While COX-2 is an excellent therapeutic target for treating breast cancer in combination with other drugs, thrombo-embolic side effects of COX-2 inhibitors noted after prolonged use in arthritis patients [120,121] calls for alternative targets downstream of COX-2 that may spare the side effects. Here, PTGS2 is linked to arthritic joint disease.